Kaitlyn R Hay1, Andrew S Huhn, David Andrew Tompkins, Kelly E Dunn. 1. Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine, Baltimore, MD (KRH, ASH, DAT, KED); Department of Psychiatry, UCSF School of Medicine, San Francisco, CA (DAT).
Abstract
BACKGROUND: While most opioid use disorder (OUD) treatment providers consider opioid abstinence to be the preferred outcome, little is known about the treatment preferences of the larger population of individuals who engage in nonmedical opioid use and have not yet sought treatment. This study sought to descriptively quantify the proportion of out-of-treatment individuals with nonmedical opioid use that have abstinent and nonabstinent recovery goals. METHODS: Participants (N = 235) who engage in nonmedical opioid use and met self-reported criteria for OUD were recruited online and participated in a cross-sectional survey on recovery goals and treatment perceptions. Participants were dichotomized as having either abstinent (70.6%) or nonabstinent (29.4%) recovery goals. Participants were presented with 13 treatment options and asked which treatment they would "try first" and which treatment they thought would be the best option for long-term recovery. RESULTS: Persons in the nonabstinent group were more likely to want to continue use of prescription opioids as prescribed by a physician compared with the abstinent group (χ[1] = 9.71, P = 0.002). There were no group differences regarding preference for individual OUD treatments. The most frequently endorsed treatments that participants would "try first" were physician visits (23.4%), one-on-one counseling (18.7%), and 12-step groups (13.2%), whereas the most frequently endorsed treatments for long-term recovery were one-on-one counseling (17.4%), residential treatment (16.7%), and buprenorphine (15.3%). CONCLUSION: Public health initiatives to engage out-of-treatment individuals should take into account recovery goals and treatment preferences to maximize treatment initiation and retention.
BACKGROUND: While most opioid use disorder (OUD) treatment providers consider opioid abstinence to be the preferred outcome, little is known about the treatment preferences of the larger population of individuals who engage in nonmedical opioid use and have not yet sought treatment. This study sought to descriptively quantify the proportion of out-of-treatment individuals with nonmedical opioid use that have abstinent and nonabstinent recovery goals. METHODS:Participants (N = 235) who engage in nonmedical opioid use and met self-reported criteria for OUD were recruited online and participated in a cross-sectional survey on recovery goals and treatment perceptions. Participants were dichotomized as having either abstinent (70.6%) or nonabstinent (29.4%) recovery goals. Participants were presented with 13 treatment options and asked which treatment they would "try first" and which treatment they thought would be the best option for long-term recovery. RESULTS:Persons in the nonabstinent group were more likely to want to continue use of prescription opioids as prescribed by a physician compared with the abstinent group (χ[1] = 9.71, P = 0.002). There were no group differences regarding preference for individual OUD treatments. The most frequently endorsed treatments that participants would "try first" were physician visits (23.4%), one-on-one counseling (18.7%), and 12-step groups (13.2%), whereas the most frequently endorsed treatments for long-term recovery were one-on-one counseling (17.4%), residential treatment (16.7%), and buprenorphine (15.3%). CONCLUSION: Public health initiatives to engage out-of-treatment individuals should take into account recovery goals and treatment preferences to maximize treatment initiation and retention.
Authors: Roger D Weiss; Jennifer Sharpe Potter; David A Fiellin; Marilyn Byrne; Hilary S Connery; William Dickinson; John Gardin; Margaret L Griffin; Marc N Gourevitch; Deborah L Haller; Albert L Hasson; Zhen Huang; Petra Jacobs; Andrzej S Kosinski; Robert Lindblad; Elinore F McCance-Katz; Scott E Provost; Jeffrey Selzer; Eugene C Somoza; Susan C Sonne; Walter Ling Journal: Arch Gen Psychiatry Date: 2011-11-07
Authors: Stephen F Butler; Kathrine Fernandez; Christine Benoit; Simon H Budman; Robert N Jamison Journal: J Pain Date: 2008-01-22 Impact factor: 5.820
Authors: Andrew S Huhn; J Gregory Hobelmann; Justin C Strickland; George A Oyler; Cecilia L Bergeria; Annie Umbricht; Kelly E Dunn Journal: JAMA Netw Open Date: 2020-02-05
Authors: Neil B Varshneya; Kelly E Dunn; Caitlyn J Grubb; Sandra I Okobi; Andrew S Huhn; Cecilia L Bergeria Journal: Exp Clin Psychopharmacol Date: 2022-03-10 Impact factor: 3.492
Authors: Forrest Toegel; Matthew D Novak; Andrew M Rodewald; Jeannie-Marie Leoutsakos; Kenneth Silverman; August F Holtyn Journal: Psychol Addict Behav Date: 2021-07-29
Authors: Sean Esteban McCabe; Carol J Boyd; Rebecca J Evans-Polce; Vita V McCabe; John E Schulenberg; Philip T Veliz Journal: J Addict Med Date: 2021 May-Jun 01 Impact factor: 4.647
Authors: Andrew S Huhn; Eric C Strain; Jasmyne Jardot; Gavin Turner; Cecilia L Bergeria; Sandeep Nayak; Kelly E Dunn Journal: J Addict Med Date: 2022 Jan-Feb 01 Impact factor: 3.702